1. Increased use of higher-cost medicines continues to put pressure on Canadian public drug plans. In: Government of Canada. 2021 [cited 26 Nov 2022]. https://www.canada.ca/en/patented-medicine-prices-review/news/2021/11/increased-use-of-higher-cost-medicines-continues-to-put-pressure-on-canadian-public-drug-plans.html.
2. EUnetHTA methodological guideline—methods for health economic evaluations. In: EUnetHTA. 2015 [cited 26 Nov 2022]. https://www.eunethta.eu/eunethta-methodological-guideline-methods-for-health-economic-evaluations/.
3. Pan-Canadian Pharmaceutical Alliance (pCPA). The Negotiation Process. [cited 26 Nov 2022]. https://www.pcpacanada.ca/negotiation-process.
4. Paulden M. Calculating and interpreting ICERs and net benefit. Pharmacoeconomics. 2020. https://doi.org/10.1007/s40273-020-00914-6.
5. Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J Health Serv Res Policy. 2007;12:56–8.